Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Chlordiazepoxide is a benzodiazepine used primarily for the management of anxiety disorders and for the short-term relief of symptoms of anxiety. It is also indicated for the treatment of withdrawal symptoms associated with acute alcoholism and preoperative apprehension and anxiety. Chlordiazepoxide acts as a central nervous system depressant by enhancing the effect of gamma-aminobutyric acid (GABA), an inhibitory neurotransmitter in the brain, thereby decreasing abnormal electrical activity. The drug possesses anxiolytic, sedative, hypnotic, anticonvulsant, and amnesic properties. In addition to its use as a single agent, chlordiazepoxide is available in combination products with clidinium (for gastrointestinal disorders) and amitriptyline (for depression). It was developed by Hoffmann-La Roche in the late 1950s[3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Chlordiazepoxide.